BC Week In Review | Oct 18, 2010
Clinical News

BioPlex 2200 Anti-CCP test regulatory update

FDA granted 510(k) clearance to Bio-Rad's BioPlex 2200 Anti-CCP test for the early detection of rheumatoid arthritis. Bio-Rad said it also launched the test in the U.S. and already markets it outside the U.S. The...
BC Week In Review | Jan 11, 2010
Company News

Bio-Rad Laboratories sales and marketing update

Bio-Rad launched its BioPlex 2200 Anti-CCP test in Australia, Canada, France, Israel, South Africa and the U.K. to detect rheumatoid arthritis. The assay, which measures anti-cyclic citrullinated peptide antibodies (anti-CCP), will run on Bio-Rad's BioPlex...
Items per page:
1 - 2 of 2